Metabolite profiles and mass balance of fuzuloparib, a novel poly (ADP‐ribose) polymerase inhibitor, in subjects with advanced solid cancers.

MLA

Bian, Yicong, et al. “Metabolite Profiles and Mass Balance of Fuzuloparib, a Novel Poly (ADP‐ribose) Polymerase Inhibitor, in Subjects with Advanced Solid Cancers.” British Journal of Clinical Pharmacology, vol. 88, no. 7, July 2022, pp. 3307–20. EBSCOhost, https://doi.org/10.1111/bcp.15256.

APA

Bian, Y., Meng, J., Ma, S., Li, G., Wang, Y., Li, S., Liu, L., Huang, C., Zhang, H., Zhong, D., & Miao, L. (2022). Metabolite profiles and mass balance of fuzuloparib, a novel poly (ADP‐ribose) polymerase inhibitor, in subjects with advanced solid cancers. British Journal of Clinical Pharmacology, 88(7), 3307–3320. https://doi.org/10.1111/bcp.15256

Chicago

Bian, Yicong, Jian Meng, Sheng Ma, Guangze Li, Yuya Wang, Shaorong Li, Linsheng Liu, et al. 2022. “Metabolite Profiles and Mass Balance of Fuzuloparib, a Novel Poly (ADP‐ribose) Polymerase Inhibitor, in Subjects with Advanced Solid Cancers.” British Journal of Clinical Pharmacology 88 (7): 3307–20. doi:10.1111/bcp.15256.